Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Langsigtet observationel, prospektiv, multicenterundersøgelse, der skal indsamles i en befolkning i den virkelige verden om behandlingsmønsteret for secukinumAb hos voksne patienter med moderat til svær Hidradenitis Suppurativa. (ANIMA)

13. november 2026 opdateret af: Novartis Pharmaceuticals

Langsigtet observAtionel, prospektiv, multicenterundersøgelse, der skal indsamles i en virkelig verden-befolkning data om behandlingsmønsteret for secukinumAb hos voksne patienter med moderat til svær Hidradenitis Suppurativa (HS) (ANIMA)

The purpose of this observational, prospective, non-interventional, multicenter, open-label, single arm study in Hidradenitis suppurativa (HS) is to assess the treatment pattern of secukinumab in a flexible dosing regimen and decision influencing factors for flexible dosing in a real-world population over 2 years.

Studieoversigt

Status

Aktiv, ikke rekrutterende

Intervention / Behandling

Detaljeret beskrivelse

The study will collect data from patients during routine secukinumab treatment and will be representative of the real-world patient population eligible for secukinumab treatment in Germany.

In order to attain widespread representation of health care practices related to the use of secukinumab in the approved indication of moderate to severe HS, a broad spectrum of dermatology practices and clinics who are treating patients with HS across Germany will be included.

Undersøgelsestype

Observationel

Tilmelding (Faktiske)

436

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • Aachen, Tyskland, 52064
        • Novartis Investigative Site
      • Ahaus, Tyskland, 48683
        • Novartis Investigative Site
      • Annaberg-Buchholz, Tyskland, 09456
        • Novartis Investigative Site
      • Bad Steben, Tyskland, 95138
        • Novartis Investigative Site
      • Baden-Baden, Tyskland, 76530
        • Novartis Investigative Site
      • Berlin, Tyskland, 12159
        • Novartis Investigative Site
      • Berlin, Tyskland, 13595
        • Novartis Investigative Site
      • Bielefeld, Tyskland, 33647
        • Novartis Investigative Site
      • Bochum, Tyskland, 44791
        • Novartis Investigative Site
      • Bonn, Tyskland, 53105
        • Novartis Investigative Site
      • Brandenburg, Tyskland, 14776
        • Novartis Investigative Site
      • Bremen, Tyskland, 28359
        • Novartis Investigative Site
      • Buxtehude, Tyskland, 21614
        • Novartis Investigative Site
      • Bückeburg, Tyskland, 31675
        • Novartis Investigative Site
      • Chemnitz, Tyskland, 09117
        • Novartis Investigative Site
      • Chemnitz, Tyskland, 09113
        • Novartis Investigative Site
      • Cologne, Tyskland, 51065
        • Novartis Investigative Site
      • Delitzsch, Tyskland, 04509
        • Novartis Investigative Site
      • Dessau, Tyskland, 06847
        • Novartis Investigative Site
      • Dorsten, Tyskland, 46282
        • Novartis Investigative Site
      • Dortmund, Tyskland, 44137
        • Novartis Investigative Site
      • Dresden, Tyskland, 01309
        • Novartis Investigative Site
      • Düren, Tyskland, 52349
        • Novartis Investigative Site
      • Emsdetten, Tyskland, 48282
        • Novartis Investigative Site
      • Erlangen, Tyskland, 91054
        • Novartis Investigative Site
      • Falkenberg, Tyskland, 04895
        • Novartis Investigative Site
      • Falkensee, Tyskland, 14612
        • Novartis Investigative Site
      • Freising, Tyskland, 85354
        • Novartis Investigative Site
      • Geilenkirchen, Tyskland, 52511
        • Novartis Investigative Site
      • Gera, Tyskland, 07548
        • Novartis Investigative Site
      • Gernsbach, Tyskland, 76593
        • Novartis Investigative Site
      • Gladbeck, Tyskland, 45964
        • Novartis Investigative Site
      • Großenhain, Tyskland, 01558
        • Novartis Investigative Site
      • Hamburg, Tyskland, 20246
        • Novartis Investigative Site
      • Hamburg, Tyskland, 22143
        • Novartis Investigative Site
      • Hanover, Tyskland, 30159
        • Novartis Investigative Site
      • Haslach im Kinzigtal, Tyskland, 77716
        • Novartis Investigative Site
      • Hofgeismar, Tyskland, 34369
        • Novartis Investigative Site
      • Jena, Tyskland, 07743
        • Novartis Investigative Site
      • Jülich, Tyskland, 52428
        • Novartis Investigative Site
      • Karlsruhe, Tyskland, 76133
        • Novartis Investigative Site
      • Kempen, Tyskland, 47906
        • Novartis Investigative Site
      • Lübeck, Tyskland, 23538
        • Novartis Investigative Site
      • Magdeburg, Tyskland, 39120
        • Novartis Investigative Site
      • Magdeburg, Tyskland, 39104
        • Novartis Investigative Site
      • Mainz, Tyskland, 55116
        • Novartis Investigative Site
      • Marburg, Tyskland, 35043
        • Novartis Investigative Site
      • Minden, Tyskland, 32429
        • Novartis Investigative Site
      • Mönchengladbach, Tyskland, 41063
        • Novartis Investigative Site
      • Neu Wulmstorf, Tyskland, 21629
        • Novartis Investigative Site
      • Nuremberg, Tyskland, 90419
        • Novartis Investigative Site
      • Oberasbach, Tyskland, 90522
        • Novartis Investigative Site
      • Oelde, Tyskland, 59302
        • Novartis Investigative Site
      • Peitz, Tyskland, 03185
        • Novartis Investigative Site
      • Potsdam, Tyskland, 14469
        • Novartis Investigative Site
      • Remscheid, Tyskland, 42897
        • Novartis Investigative Site
      • Selters, Tyskland, 56242
        • Novartis Investigative Site
      • Simmern, Tyskland, 55469
        • Novartis Investigative Site
      • Soest, Tyskland, 59494
        • Novartis Investigative Site
      • Stolberg, Tyskland, 52222
        • Novartis Investigative Site
      • Unna, Tyskland, 59423
        • Novartis Investigative Site
      • Wittlich, Tyskland, 54316
        • Novartis Investigative Site
      • Wuppertal, Tyskland, 42103
        • Novartis Investigative Site
    • Baden-Wurttemberg
      • Freiburg im Breisgau, Baden-Wurttemberg, Tyskland, 79068
        • Novartis Investigative Site
      • Rheinstetten, Baden-Wurttemberg, Tyskland, 76287
        • Novartis Investigative Site
    • Bavaria
      • Haßfurt, Bavaria, Tyskland, 97437
        • Novartis Investigative Site
      • Kulmbach, Bavaria, Tyskland, 95326
        • Novartis Investigative Site
      • Lauf an der Pegnitz, Bavaria, Tyskland, 91207
        • Novartis Investigative Site
      • Nuremberg, Bavaria, Tyskland, 90402
        • Novartis Investigative Site
    • Brandenburg
      • Panketal, Brandenburg, Tyskland, 16341
        • Novartis Investigative Site
    • Free and Hanseatic City of Hamburg
      • Hamburg, Free and Hanseatic City of Hamburg, Tyskland, 22549
        • Novartis Investigative Site
    • Lower Saxony
      • Lingen, Lower Saxony, Tyskland, 49809
        • Novartis Investigative Site
    • Mecklenburg-Vorpommern
      • Bergen auf Rügen, Mecklenburg-Vorpommern, Tyskland, 18528
        • Novartis Investigative Site
      • Kröpelin, Mecklenburg-Vorpommern, Tyskland, 18236
        • Novartis Investigative Site
    • North Rhine-Westphalia
      • Krefeld, North Rhine-Westphalia, Tyskland, 47798
        • Novartis Investigative Site
    • Rhineland-Palatinate
      • Mainz, Rhineland-Palatinate, Tyskland, 55128
        • Novartis Investigative Site
    • Saxony
      • Dresden, Saxony, Tyskland, 01307
        • Novartis Investigative Site
      • Leipzig, Saxony, Tyskland, 04207
        • Novartis Investigative Site
      • Leipzig, Saxony, Tyskland, 04289
        • Novartis Investigative Site
    • Saxony-Anhalt
      • Wittenberg, Saxony-Anhalt, Tyskland, 06886
        • Novartis Investigative Site

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 99 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Prøveudtagningsmetode

Ikke-sandsynlighedsprøve

Studiebefolkning

patients, being treated for HS with secukinumab according to the summary of product characteristics (SmPC), after the approval of secukinumab has been granted in this indication.

Beskrivelse

Inclusion Criteria:

Patients eligible for inclusion in this study have to fulfill all of the following criteria at enrollment:

  1. Patients who provide written informed consent to participate in the study
  2. Male and female patients with ≥18 years of age
  3. Diagnosis of clinically unequivocal moderate to severe HS
  4. Patients for whom a therapy with secukinumab is medically indicated
  5. Documented decision for treatment with marketed secukinumab regardless of this noninterventional study
  6. Treatment with secukinumab according to the latest version of SmPC
  7. Initial treatment with marketed secukinumab planned for up to 1 week before the baseline visit

Exclusion Criteria:

Patients fulfilling any of the following criteria at enrollment are not eligible for inclusion in this study. No additional exclusions may be applied by the investigator, in order to ensure that the study population will be representative of all eligible patients:

  1. Patients who have any contraindications, such as a history of or active inflammatory bowel disease (Crohn´s disease, ulcerative colitis), and are not eligible for treatment with secukinumab according to the SmPC
  2. Any medical or psychological condition in the treating physician's opinion which may prevent the patient from the study participation
  3. Simultaneous participation in any investigational trial or simultaneous participation in another Novartis-sponsored non-interventional study with secukinumab
  4. Previous exposure to IL-17 inhibitors
  5. For biologic-naïve patients, previous exposure to another biologic drug, such as anti-TNF-α inhibitors

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Observationsmodeller: COHORT
  • Tidsperspektiver: PROSPECTIVE

Kohorter og interventioner

Gruppe / kohorte
Intervention / Behandling
secukinumab

Patients being treated for HS with secukinumab according to the summary of product characteristics (SmPC), after the approval of secukinumab has been granted in this indication.

Prospective observational study. There is no treatment allocation. Patients administered secukinumab by prescription and administered according to the SmPC.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Proportion of patients receiving up-titration
Tidsramme: Up to 24 months

Proportion of patients receiving up-titration (q4w-to-q2w)

Up to 24 months
Proportion of patients receiving down-titration
Tidsramme: Up to 24 months

Proportion of patients receiving down-titration (q2w-to-q4w)

Up to 24 months
Time to up-titration and down-titration
Tidsramme: Up to 2 years

Time to up-titration and down-titration

Up to 2 years
Duration of q4w treatment with secukinumab after dose reduction
Tidsramme: Up to 2 years

Duration of q4w treatment with secukinumab after dose reduction

Up to 2 years
Proportion of patients who receive more than one up-and/or down titration
Tidsramme: Up to 24 months

Proportion of patients who receive more than one up-and/or down titration

Up to 24 months
Proportion of patients receiving HS-specific concomitant treatments in combination with secukinumab
Tidsramme: Up to 2 years

Proportion of patients receiving HS-specific concomitant treatments in combination with secukinumab

Up to 2 years
Number and type of surgical interventions
Tidsramme: Up to 2 years

Number and type of surgical interventions

  • minor and major surgical excision;
  • inpatient, outpatient
Up to 2 years
Proportion of patients achieving 55% reduction in IHS4 (IHS4-55)
Tidsramme: Up to 24 months

The IHS4 is an exclusively physician-based, clinical scoring system for dynamic assessment of HS severity.

HS severity is calculated based on the number of lesions multiplied by their respective score: the IHS4 score (points) = (number of nodules multiplied by 1) + (number of abscesses multiplied by 2) + [number of draining tunnels (fistulae/sinuses) multiplied by 4]. A score of 3 or less signifies mild HS, a score of 4-10 signifies moderate HS and a score of 11 or higher signifies severe HS

Up to 24 months
mean change of International Hidradenitis Suppurativa Severity Score System (IHS4)
Tidsramme: Up to 24 months

The IHS4 is an exclusively physician-based, clinical scoring system for dynamic assessment of HS severity.

HS severity is calculated based on the number of lesions multiplied by their respective score: the IHS4 score (points) = (number of nodules multiplied by 1) + (number of abscesses multiplied by 2) + [number of draining tunnels (fistulae/sinuses) multiplied by 4]. A score of 3 or less signifies mild HS, a score of 4-10 signifies moderate HS and a score of 11 or higher signifies severe HS

Up to 24 months
Proportion of patients achieving a 5-point reduction of their Dermatology Life Quality Index (DLQI) questionnaire
Tidsramme: Up to 24 months

The DLQI is a 10-item general dermatology disability index designed to assess health-related quality of life (HRQoL) in adult subjects with skin diseases such as eczema, psoriasis, acne, and viral warts. The measure is self-administered and includes domains of daily activities, leisure, personal relationships, symptoms and feelings, treatment, and work/school.

Each item has four response categories ranging from 0 (not at all) to 3 (very much). "Not relevant" is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions. Scores range from 0 to 30, with higher scores indicating greater HRQoL impairment.

Up to 24 months
Mean reduction of Abscesses and inflammatory nodules (AN) count
Tidsramme: Up to 24 months

Mean reduction of Abscesses and inflammatory nodules (AN) count

Up to 24 months
Proportion of patients achieving a 30% reduction of pain Numerical Rating scale 30 (NRS30)
Tidsramme: Up to 24 months

The NRS is a segmented numeric version of the visual analog scale (VAS) in which a respondent selects a whole number (0-10 integers) that best reflects the intensity of their pain ranging from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). To assess this, the patient should concentrate on the pain that his/her skin lesions generate. The Patient's Global Assessment of Skin Pain - NRS will be completed by the subject electronically via a web-based application or in paper form.

Up to 24 months

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Studieleder: Novartis Pharmaceuticals, Novartis Pharmaceuticals

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

10. august 2023

Primær færdiggørelse (Anslået)

31. marts 2027

Studieafslutning (Anslået)

31. marts 2027

Datoer for studieregistrering

Først indsendt

16. juni 2023

Først indsendt, der opfyldte QC-kriterier

26. juni 2023

Først opslået (Faktiske)

28. juni 2023

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

16. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

13. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner